Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A11QVV0
Tue, 28.06.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Reports Outcome of the Annual General Meeting 2022 Ladenburg, Germany, 28 June 2022 – Heidelberg Pharma AG (FSE: HPHA) announced that the shareholders of the Company approved the resolutions of the administration with large majorities (ranged from 98.49% to 99.99%) during the virtual Annual General Meeting today:  [ … ]
Technical analysis
To the publication
Tue, 28.06.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Reports Outcome of the Annual General Meeting 2022 Ladenburg, Germany, 28 June 2022 – Heidelberg Pharma AG (FSE: HPHA) announced that the shareholders of the Company approved the resolutions of the administration with large majorities (ranged from 98.49% to 99.99%) during the virtual Annual General Meeting today:  [ … ]
Technical analysis
To the publication
Thu, 28.04.2022       Heidelberg Pharma AG
DE000A11QVV0

Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022 - Start of clinical trial with HDP-101 in multiple myeloma - Financing commitment of up to EUR 36 million obtained from main shareholder dievini - Signing of a strategic partnership with Huadong Medicine with an overall volume of up to one billion US dollars - Fin [ … ]
Technical analysis
To the publication
Thu, 07.04.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma to Present New Data on its Proprietary ATAC(R) Technology Platform at the AACR Annual Meeting 2022 Ladenburg, Germany, 7 April 2022 - Heidelberg Pharma AG (FSE: HPHA) announced today that it will present preclinical data on its proprietary Amanitin-based ATAC(R) technology at the American Association for Cancer Res [ … ]
Technical analysis
To the publication
Thu, 24.03.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma announces financial figures for fiscal year 2021 and provides business update - Start of clinical trial with HDP-101 in multiple myeloma - Signing of strategic partnership with Huadong Medicine - Successful financing activities - Financial figures in line with adjusted forecast - Conference call to be held on 24 Ma [ … ]
Technical analysis
To the publication
Thu, 10.03.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117 Ladenburg, Germany, 10 March 2022 - Heidelberg Pharma AG (FSE: HPHA) today announced that its cooperation partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta; NASDAQ: MGTA) has dosed the first patient with the developm [ … ]
Technical analysis
To the publication
Mon, 28.02.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment - Heidelberg Pharma grants Huadong exclusive license to develop and commercialize HDP-101 and HDP-103 in Asia[1] (excluding Japan), plus exclusive opt-in rights for two more pipeline candidates, with a total deal value of up to USD 930 million  [ … ]
Technical analysis
To the publication
Tue, 15.02.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma Ladenburg, Germany, 15 February 2022 - Heidelberg Pharma AG (FSE: HPHA) today announced that the first patient has been dosed with HDP-101 in a Phase I/IIa study at the Winship Cancer Institute of Emory University, A [ … ]
Technical analysis
To the publication
Thu, 28.10.2021       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Participates at Various Conferences Ladenburg, Germany, 28 October 2021 - Heidelberg Pharma AG (FSE: HPHA) will present the company and its proprietary ATAC technology at several upcoming scientific and investor conferences. Heidelberg Pharma uses Amanitin as an innovative toxin to develop new cancer therapies tha [ … ]
Technical analysis
To the publication
Thu, 07.10.2021       Heidelberg Pharma AG
DE000A11QVV0

Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2021 - Paul-Ehrlich-Institut follows the FDA in giving clearance to begin a Phase I/IIa trial of HDP-101; first trial centers initiated in the USA - Gross issue proceeds of over EUR 20 million generated from private placement in June - Significant advances made in partn [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Thursday, 04.07.2024, Calendar Week 27, 186th day of the year, 180 days remaining until EoY.